Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Gene Editing for Transplants and Cell Therapy: Luhan Yang on The Long Run
Creative New Treatments for Mental Health: Steve Paul on The Long Run
Seeking Impact: Servier’s David Lee on The Long Run Podcast
Medicines Based on Unusual Genetic Traits: Andrew Farnum on The Long Run